Disease · MONDO_0006512
Trials29
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 29
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01509625 | Retrospective Study Assessment Treatment Response Faslodex®( 500 mg) | 272 | 2016-06-01 | Malignant Neoplasm of Breast Stage IV | FULVESTRANT | Its record names the disease | ClinicalTrials.gov | |
| NCT01587703 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Phase 1 | 196 | 2020-03-16 | Carcinoma, Midline | MOLIBRESIB | Its record names the disease | ClinicalTrials.gov |
| NCT03284957 | Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer | Phase 1/2 | 136 | 2025-11-24 | Breast Cancer | ABEMACICLIB, ALPELISIB, AMCENESTRANT, EVEROLIMUS, PALBOCICLIB | Its record names the disease | ClinicalTrials.gov |
| NCT00259090 | Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer | Phase 2 | 120 | 2012-08-16 | Breast Cancer | ANASTROZOLE, FULVESTRANT | Its record names the disease | ClinicalTrials.gov |
| NCT04191382 | Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer | Phase 2 | 105 | 2022-06-29 | Breast Cancer | AMCENESTRANT, LETROZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02993159 | Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast | Phase 2 | 100 | 2024-12-18 | Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive | AFIMOXIFENE, TAMOXIFEN CITRATE | Its record names the disease | ClinicalTrials.gov |
| NCT05659563 | Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% | Phase 2 | 92 | 2026-03-19 | Breast Cancer, Breast Cancer, Early-Onset | GIREDESTRANT, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov |
| NCT02311933 | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer | Phase 2 | 81 | 2021-09-28 | Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7 | ENDOXIFEN, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov |
| NCT02392611 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer | Phase 1 | 33 | 2020-12-29 | Solid Tumors and Lymphomas | ALOBRESIB, EXEMESTANE, FULVESTRANT | Its record names the disease | ClinicalTrials.gov |
| NCT03620643 | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours | Phase 2 | 33 | 2025-10-30 | Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation | CRIZOTINIB, FULVESTRANT | Its record names the disease | ClinicalTrials.gov |
| NCT02953860 | Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer | Phase 2 | 32 | 2021-05-14 | Breast Cancer | ENZALUTAMIDE, FULVESTRANT | Its record names the disease | ClinicalTrials.gov |
| NCT02907918 | Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer | Phase 2 | 26 | 2021-09-05 | Breast Cancer, Cancer of Breast, Breast Carcinoma | LETROZOLE, PALBOCICLIB, TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01368263 | Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer | Phase 2 | 8 | 2015-02-20 | Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer | ANASTROZOLE, GOSERELIN ACETATE, LETROZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT03926091 | Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer | Phase 3 | 2,172 | Breast Cancer | CYCLOPHOSPHAMIDE, DOCETAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT01613560 | Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy | Phase 2 | 404 | Breast Cancer | TAMOXIFEN | Its record names the disease | ClinicalTrials.gov | |
| NCT03011684 | Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial | Phase 3 | 309 | Infertility | LETROZOLE, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov | |
| NCT01589367 | Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer | Phase 2 | 208 | Hormone Receptor Positive Malignant Neoplasm of Breast | METFORMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04571437 | Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) | Phase 2 | 204 | Breast Cancer, Estrogen Receptor-positive Breast Cancer, Metastatic Breast Cancer | CAPECITABINE, LETROZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT02580448 | CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) | Phase 1/2 | 175 | Cancer of the Breast, Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Male Breast Cancer, Triple Negative Breast Cancer, ER+ Breast Cancer | SEVITERONEL | Its record names the disease | ClinicalTrials.gov | |
| NCT01234857 | A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | Phase 2 | 115 | Breast Cancer | DALOTUZUMAB, RIDAFOROLIMUS | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006512/trials